Evidence & regulatory context
- Mechanism
- ChEMBL not queried: bacterial glycosaminoglycan-degrading enzymes have no small-molecule ChEMBL entity. ClinicalTrials.gov searched twice ('chondroitinase OR keratanase', then 'chondroitinase ABC'); ALL 12 raw hits were term collisions with recombinant human HYALURONIDASE (rHuPH20, PEGPH20, HYQVIA) or unrelated anaesthesia and oncology studies, and were REJECTED. No human trial of keratanase II or chondroitinase ABC exists in the registry. to_trial=false is a searched negative result.
- Target
- Not recorded
- Injury models
- Spinal cord injury
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatSpinal cord injuryUnspecifiedSprague-DawleyFemaleLocal administration at the lesionAfter spinal cord injury
Model: Cervical spinal cord injury at C3/4
The combination of keratan sulfate digestion and rehabilitation gave a better pellet removal rate than either alone, although not statistically significant, while both keratanase II and chondroitinase ABC combined with rehabilitation significantly increased neurite growth.
Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.
